Cargando…

No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro

Gliflozins are inhibitors of the renal proximal tubular sodium-glucose co-transporter-2 (SGLT-2), that inhibit reabsorption of urinary glucose and they are able to reduce hyperglycemia in patients with type 2 diabetes. A renoprotective function of gliflozins has been proven in diabetic nephropathy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Baer, Patrick C., Koch, Benjamin, Freitag, Janina, Schubert, Ralf, Geiger, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013746/
https://www.ncbi.nlm.nih.gov/pubmed/31936266
http://dx.doi.org/10.3390/ijms21020391
_version_ 1783496474910261248
author Baer, Patrick C.
Koch, Benjamin
Freitag, Janina
Schubert, Ralf
Geiger, Helmut
author_facet Baer, Patrick C.
Koch, Benjamin
Freitag, Janina
Schubert, Ralf
Geiger, Helmut
author_sort Baer, Patrick C.
collection PubMed
description Gliflozins are inhibitors of the renal proximal tubular sodium-glucose co-transporter-2 (SGLT-2), that inhibit reabsorption of urinary glucose and they are able to reduce hyperglycemia in patients with type 2 diabetes. A renoprotective function of gliflozins has been proven in diabetic nephropathy, but harmful side effects on the kidney have also been described. In the current project, primary highly purified human renal proximal tubular epithelial cells (PTCs) have been shown to express functional SGLT-2, and were used as an in vitro model to study possible cellular damage induced by two therapeutically used gliflozins: empagliflozin and dapagliflozin. Cell viability, proliferation, and cytotoxicity assays revealed that neither empagliflozin nor dapagliflozin induce effects in PTCs cultured in a hyperglycemic environment, or in co-medication with ramipril or hydro-chloro-thiazide. Oxidative stress was significantly lowered by dapagliflozin but not by empagliflozin. No effect of either inhibitor could be detected on mRNA and protein expression of the pro-inflammatory cytokine interleukin-6 and the renal injury markers KIM-1 and NGAL. In conclusion, empa- and dapagliflozin in therapeutic concentrations were shown to induce no direct cell injury in cultured primary renal PTCs in hyperglycemic conditions.
format Online
Article
Text
id pubmed-7013746
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70137462020-03-09 No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro Baer, Patrick C. Koch, Benjamin Freitag, Janina Schubert, Ralf Geiger, Helmut Int J Mol Sci Article Gliflozins are inhibitors of the renal proximal tubular sodium-glucose co-transporter-2 (SGLT-2), that inhibit reabsorption of urinary glucose and they are able to reduce hyperglycemia in patients with type 2 diabetes. A renoprotective function of gliflozins has been proven in diabetic nephropathy, but harmful side effects on the kidney have also been described. In the current project, primary highly purified human renal proximal tubular epithelial cells (PTCs) have been shown to express functional SGLT-2, and were used as an in vitro model to study possible cellular damage induced by two therapeutically used gliflozins: empagliflozin and dapagliflozin. Cell viability, proliferation, and cytotoxicity assays revealed that neither empagliflozin nor dapagliflozin induce effects in PTCs cultured in a hyperglycemic environment, or in co-medication with ramipril or hydro-chloro-thiazide. Oxidative stress was significantly lowered by dapagliflozin but not by empagliflozin. No effect of either inhibitor could be detected on mRNA and protein expression of the pro-inflammatory cytokine interleukin-6 and the renal injury markers KIM-1 and NGAL. In conclusion, empa- and dapagliflozin in therapeutic concentrations were shown to induce no direct cell injury in cultured primary renal PTCs in hyperglycemic conditions. MDPI 2020-01-08 /pmc/articles/PMC7013746/ /pubmed/31936266 http://dx.doi.org/10.3390/ijms21020391 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Baer, Patrick C.
Koch, Benjamin
Freitag, Janina
Schubert, Ralf
Geiger, Helmut
No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
title No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
title_full No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
title_fullStr No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
title_full_unstemmed No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
title_short No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
title_sort no cytotoxic and inflammatory effects of empagliflozin and dapagliflozin on primary renal proximal tubular epithelial cells under diabetic conditions in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013746/
https://www.ncbi.nlm.nih.gov/pubmed/31936266
http://dx.doi.org/10.3390/ijms21020391
work_keys_str_mv AT baerpatrickc nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro
AT kochbenjamin nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro
AT freitagjanina nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro
AT schubertralf nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro
AT geigerhelmut nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro